Published in Int J Mol Sci on September 01, 2015
Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev (2017) 0.78
Effects of the Sijunzi decoction on the immunological function in rats with dextran sulfate-induced ulcerative colitis. Biomed Rep (2016) 0.78
Role of MiRNAs in Inflammatory Bowel Disease. Dig Dis Sci (2017) 0.75
Eosinophils in Autoimmune Diseases. Front Immunol (2017) 0.75
Macrophage Subset Expressing CD169 in Peritoneal Cavity-Regulated Mucosal Inflammation Together with Lower Levels of CCL22. Inflammation (2017) 0.75
Huangqin-Tang and Ingredients in Modulating the Pathogenesis of Ulcerative Colitis. Evid Based Complement Alternat Med (2017) 0.75
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem (2007) 10.41
Genetics and pathogenesis of inflammatory bowel disease. Nature (2011) 7.79
Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol (2006) 7.75
Regulation of inflammatory responses by IL-17F. J Exp Med (2008) 5.56
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 5.36
A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol (2009) 5.26
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
The IL-23/IL-17 axis in inflammation. J Clin Invest (2006) 4.32
Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol (2004) 3.41
Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis (2006) 3.09
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol (2005) 2.90
Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology (2011) 2.90
Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol (2014) 2.74
Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology (2011) 2.52
Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol (2003) 2.50
Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut (2004) 2.29
Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci (2000) 2.26
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology (2000) 2.17
Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis (2008) 1.96
Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat Immunol (2013) 1.88
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis (2007) 1.85
Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum (2004) 1.79
Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J Gastroenterol Hepatol (2008) 1.79
Th17 cells: from precursors to players in inflammation and infection. Int Immunol (2009) 1.77
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther (2006) 1.76
Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.75
IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis (2007) 1.71
IL-23/IL-17 axis in IBD. Inflamm Bowel Dis (2010) 1.71
Antigen processing and presentation by intestinal epithelial cells - polarity and complexity. Immunol Today (2000) 1.65
Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol (2007) 1.65
Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr (2000) 1.63
An update on the use and investigation of probiotics in health and disease. Gut (2013) 1.62
Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut (2004) 1.62
Insights from mouse models of colitis. J Leukoc Biol (2000) 1.60
Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun (2008) 1.56
A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis (2005) 1.55
RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature (2014) 1.53
The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol (2008) 1.44
IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol (2012) 1.44
Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther (2008) 1.40
Th17 cells in immunity and autoimmunity. Clin Dev Immunol (2013) 1.40
IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect (2013) 1.37
Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol (2009) 1.33
Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr (2003) 1.32
Probiotic effects on inflammatory bowel disease. J Nutr (2007) 1.29
Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis (2013) 1.25
Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol (2004) 1.23
Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc (2007) 1.20
Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther (2003) 1.19
Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. Br J Clin Pharmacol (2008) 1.18
Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of gammadeltaT and regulatory T cells of intestinal intraepithelial lymphocytes. Inflamm Bowel Dis (2009) 1.16
Mechanisms involved in alleviation of intestinal inflammation by bifidobacterium breve soluble factors. PLoS One (2009) 1.15
Do studies in humans better depict Th17 cells? Blood (2009) 1.14
Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate. Scand J Gastroenterol (2000) 1.13
Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol (2005) 1.12
Effect of natural commensal-origin DNA on toll-like receptor 9 (TLR9) signaling cascade, chemokine IL-8 expression, and barrier integritiy of polarized intestinal epithelial cells. Inflamm Bowel Dis (2010) 1.11
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther (2005) 1.10
Lactobacillus fermentum ACA-DC 179 displays probiotic potential in vitro and protects against trinitrobenzene sulfonic acid (TNBS)-induced colitis and Salmonella infection in murine models. Int J Food Microbiol (2007) 1.10
Bifidobacterium infantis suppresses proinflammatory interleukin-17 production in murine splenocytes and dextran sodium sulfate-induced intestinal inflammation. Int J Mol Med (2008) 1.09
Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma. Am J Physiol Gastrointest Liver Physiol (2007) 1.08
Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. Int J Food Microbiol (2006) 1.05
Heat-killed body of lactobacillus brevis SBC8803 ameliorates intestinal injury in a murine model of colitis by enhancing the intestinal barrier function. Inflamm Bowel Dis (2011) 1.04
Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN Inflamm (2014) 1.04
The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol (2013) 1.00
Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. Int J Colorectal Dis (2005) 0.99
A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br J Nutr (2007) 0.98
Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice. Int Immunopharmacol (2008) 0.97
Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice. Inflamm Bowel Dis (2009) 0.97
The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am J Pathol (2010) 0.96
IBD pathogenesis in 2014: Molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol (2014) 0.96
Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol (2006) 0.96
The effect of probiotics and gut microbiota on Th17 cells. Int Rev Immunol (2013) 0.95
Flexible cytokine production by macrophages and T cells in response to probiotic bacteria: a possible mechanism by which probiotics exert multifunctional immune regulatory activities. Gut Microbes (2011) 0.94
Crosstalk between the intestinal microbiota and the innate immune system in intestinal homeostasis and inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.92
Clinical usefulness of probiotics in inflammatory bowel diseases. J Physiol Pharmacol (2006) 0.92
Role of the IL-23/IL-17 axis in Crohn's disease. Discov Med (2012) 0.91
Induction of lamina propria Th17 cells by intestinal commensal bacteria. Vaccine (2010) 0.90
Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? Mol Nutr Food Res (2008) 0.89
Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response: involvement of intestinal epithelial costimulatory molecules. PLoS One (2013) 0.89
Probiotics and irritable bowel syndrome. World J Gastroenterol (2013) 0.88
Lactobacillus rhamnosus GG and Streptococcus thermophilus induce suppressor of cytokine signalling 3 (SOCS3) gene expression directly and indirectly via interleukin-10 in human primary macrophages. Clin Exp Immunol (2011) 0.88
4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis (2010) 0.88
Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol (2010) 0.87
Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis. Int J Inflam (2012) 0.86
Lessons from probiotic-host interaction studies in murine models of experimental colitis. Mol Nutr Food Res (2011) 0.85
Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis. World J Gastroenterol (2013) 0.84
Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. Br J Nutr (2002) 0.84
Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria. FEMS Immunol Med Microbiol (2011) 0.84
Interleukin-17 immunity in pediatric Crohn disease and ulcerative colitis. J Pediatr Gastroenterol Nutr (2013) 0.83
IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders. Pharmacol Rep (2011) 0.83
Epigenetic imprinting by commensal probiotics inhibits the IL-23/IL-17 axis in an in vitro model of the intestinal mucosal immune system. J Leukoc Biol (2012) 0.82
Lactobacillus acidophilus suppresses colitis-associated activation of the IL-23/Th17 axis. J Immunol Res (2015) 0.81
Suppression of Th17 response by Streptococcus thermophilus ST28 through induction of IFN-γ. Int J Mol Med (2011) 0.81